For laboratory research use only. This page summarises published scientific literature on Semax in plain English, in a neutral research style. It is not medical advice and contains no guidance on doses, administration or human use.
What is Semax?
Semax is a synthetic peptide derived from adrenocorticotropic hormone (ACTH), specifically comprising amino acids 4–10 of the ACTH sequence: Met-Glu-His-Phe-Arg-Trp-Gly. This heptapeptide fragment represents one of the most extensively studied nootropic peptides in the scientific literature, with particular research momentum in Eastern European and Russian neuroscience research programs.
Mechanism of Action: BDNF and NGF Upregulation
The primary mechanism of Semax’s neuroprotective and cognitive effects centres on upregulation of neurotrophic factors—critical signalling molecules that promote neuronal survival, growth, differentiation, and synaptic plasticity.
- Long-term potentiation (LTP) and long-term depression (LTD), molecular mechanisms underlying learning and memory
- Synaptic plasticity and dendritic spine density maintenance
- Neurogenesis in adult hippocampus (critical for memory formation)
- Neuronal survival and apoptosis protection against excitotoxic insults
Nerve Growth Factor (NGF) Upregulation: Semax similarly increases NGF expression, particularly in hippocampal and cortical regions. NGF facilitates cholinergic neuron survival and function, substantiating Semax’s cognitive enhancement mechanisms. NGF also mediates neuroinflammatory regulation and microglial modulation, contributing to neuroprotective effects.
Dopaminergic Modulation: Beyond neurotrophic mechanisms, Semax enhances dopaminergic neurotransmission, particularly in mesolimbic and mesocortical pathways. This dopaminergic enhancement contributes to motivation, attention, motor activity, and reward-related learning—explaining Semax’s distinct stimulating profile compared to the anxiolytic Selank.
Sigma-1 Receptor Involvement: Emerging research suggests sigma-1 receptor interaction, which mediates neuroprotection against ischaemic insult and excitotoxicity. This may partially explain Semax’s efficacy in stroke models, independent of BDNF/NGF mechanisms.
Cognitive Enhancement and Neuroprotection Research
Semax demonstrates robust cognitive enhancement across multiple preclinical learning and memory models, with mechanistic clarity provided by BDNF/NGF upregulation.
Cognitive Enhancement and ADHD-Like Focus in Research Models
Beyond its neuroprotective profile, Semax produces cognitive enhancement in normal (non-injured) brains, with effects relevant to attention, executive function, and focus models.
ADHD-Relevant Effects: The dopaminergic enhancement and improved attention/executive function profile suggests relevance to attention-deficit/hyperactivity disorder (ADHD) research models. Unlike stimulant medications (amphetamine, methylphenidate) producing non-specific arousal, Semax’s BDNF-mediated neuroprotection alongside dopaminergic modulation may produce more targeted cognitive enhancement. This distinction makes Semax interesting for comparative ADHD research and exploring alternative mechanisms to classical stimulants.
Semax vs Selank: Stimulating Versus Calming Profiles
Semax and Selank represent complementary but distinct peptide approaches to neuropeptide research, each suited to different experimental and clinical questions.
Selank Profile: Calming, anxiolytic, mildly cognitively enhancing. Produces anxiety reduction without sedation, GABAergic modulation without benzodiazepine-like effects, and dual anxiolytic-nootropic profile. No stimulation or arousal. Preferred for anxiety disorder models and conditions where anxiolysis is desired.
Semax Variants: P21, N-Acetyl Semax, and NA Semax Amidate
Multiple chemical modifications of the Semax backbone have been developed to enhance specific pharmacological properties or improve pharmacokinetics. Understanding these variants is essential for researchers selecting appropriate compounds.
Semax (Base Compound): The original heptapeptide Met-Glu-His-Phe-Arg-Trp-Gly exhibits the neuroprotective and cognitive-enhancing profile described above. Standard research form, extensively characterised.
N-Acetyl Semax Amidate (NA-Semax Amidate): A dual modification combining N-terminal acetylation with C-terminal amidation (conversion of terminal carboxyl group to amide). This modification further stabilises the peptide against C-terminal exopeptidase degradation, potentially extending duration to 6–8 hours. Early research suggests this variant may be the most stable and longest-acting form, though comparative efficacy studies remain limited.
UK Legal Status and Regulatory Framework
Understanding Semax’s UK legal status is essential for researchers and suppliers.
Current Status: Semax is not licensed as a pharmaceutical product by the MHRA. It is not classified as a controlled substance under UK drug legislation. Semax may be legally supplied for research and laboratory purposes, provided regulatory compliance is maintained.
Regulatory Compliance: Supply of Semax for research must adhere to:
- The Human Medicines Regulations 2012 (as amended) – permitting unlicensed compound supply for research
- The Medicines Act 1968 – governing investigational substance supply
- GMP standards for suppliers – ensuring product quality and purity
- REACH regulations – chemical safety compliance
UK Sourcing and Quality Assurance
UK researchers access Semax through specialised research chemical suppliers with quality assurance standards matching preclinical research requirements.
Supplier Selection Criteria: Quality suppliers provide:
- Certificates of Analysis (CoA) documenting purity, identity, and impurities
- HPLC verification of peptide purity (>95% typical)
- Mass spectrometry confirmation of molecular weight and structure
- Sterility and endotoxin testing for parenteral preparations
- Batch-to-batch consistency assurance
- GMP certification or equivalent quality standards
- Semax variant verification (P21, NA-Semax, NA-Semax Amidate) with appropriate characterisation
Storage and Delivery: Professional suppliers maintain cold-chain integrity during shipping with temperature monitoring and protective packaging. Upon arrival, researchers should verify product integrity: vial seal condition, powder appearance and colour, documentation completeness, and CoA match.
Documentation: Reputable suppliers provide Material Safety Data Sheets (MSDS), technical datasheets, Certificates of Analysis, and variant-specific characterisation data. This documentation enables full regulatory compliance and supports publication-quality compound identification in research reports.
Limits of the evidence
Published findings come from specific study designs, often in cell systems or animals, and do not transfer automatically to other settings. A paper about a molecule is not proof that any particular batch has a given biological effect. Purity data show what is in a vial; they do not show sterility, safety or suitability for any use outside the laboratory.
Laboratory handling
- Store lyophilised powder sealed, cold (−20 °C for long-term storage), dry and protected from light.
- Let vials reach room temperature before opening to limit condensation.
- Prepare solutions with suitable laboratory solvents and calibrated equipment, and label each with lot number, concentration and date.
- Split solutions into single-use aliquots and avoid repeated freeze–thaw cycles.
- Use the peptide calculator for concentration arithmetic (mg/mL).
For laboratory research use only. Semax sold by Peptides Lab UK is supplied strictly for in vitro laboratory research. It is not for human or veterinary use, and nothing on this page is medical advice or guidance on administration. UK purchasers are responsible for complying with all applicable legislation.
